073. SECUKINUMAB PROVIDES RAPID AND SUSTAINED REDUCTIONS IN DACTYLITIS AND ENTHESITIS IN PATIENTS WITH PSORIATIC ARTHRITIS: ANALYSIS OF DATA FROM THE PHASE 3 RANDOMIZED, MULTICENTRE, DOUBLE-BLIND, PLACEBO-CONTROLLED FUTURE 2 STUDY

THU0411 Secukinumab Efficacy in Anti-TNF-Naive and Anti-TNF-IR Patients with Psoriatic Arthritis: Results of a Phase 3 Multicenter, Double-Blind, Placebo-Controlled Study (Future 2)

10.1136/annrheumdis-2015-eular.2178 ◽

2015 ◽

Vol 74 (Suppl 2) ◽

pp. 345.3-346 ◽

Cited By ~ 1

Author(s):

A. Kavanaugh ◽

I.B. McInnes ◽

S. Hall ◽

H. Chinoy ◽

A. Kivitz ◽

...

Keyword(s):

Psoriatic Arthritis ◽

Controlled Study ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

THU0421 Secukinumab is Effective in Reducing Dactylitis and Enthesitis Using Multiple Measures in Patients with Psoriatic Arthritis: Data from a Phase 3 Randomized, Multicenter, Double-Blind, Placebo-Controlled Study (Future 2)

10.1136/annrheumdis-2015-eular.2276 ◽

2015 ◽

Vol 74 (Suppl 2) ◽

pp. 351.1-351 ◽

Cited By ~ 8

Author(s):

B. Kirkham ◽

I.B. McInnes ◽

P. Mease ◽

J. Kremer ◽

S. Kandala ◽

...

Keyword(s):

Psoriatic Arthritis ◽

Controlled Study ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Multiple Measures ◽

Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial

The Lancet ◽

10.1016/s0140-6736(15)61134-5 ◽

2015 ◽

Vol 386 (9999) ◽

pp. 1137-1146 ◽

Cited By ~ 422

Author(s):

Iain B McInnes ◽

Philip J Mease ◽

Bruce Kirkham ◽

Arthur Kavanaugh ◽

Christopher T Ritchlin ◽

...

Keyword(s):

Monoclonal Antibody ◽

Psoriatic Arthritis ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Interleukin 17A ◽

Faculty Opinions recommendation of Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.725609985.793524442 ◽

2016 ◽

Author(s):

Dafna Gladman

Keyword(s):

Monoclonal Antibody ◽

Psoriatic Arthritis ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Interleukin 17A ◽

THU0425 Secukinumab Improves Signs and Symptoms of Active Psoriatic Arthritis in a Phase 3 Randomized, Multicenter, Double-Blind, Placebo-Controlled Study Using a Subcutaneous Dosing Regimen (Future 2)

10.1136/annrheumdis-2015-eular.2265 ◽

2015 ◽

Vol 74 (Suppl 2) ◽

pp. 352.3-353 ◽

Cited By ~ 1

Author(s):

I.B. McInnes ◽

P. Mease ◽

B. Kirkham ◽

A. Kavanaugh ◽

C. Ritchlin ◽

...

Keyword(s):

Psoriatic Arthritis ◽

Signs And Symptoms ◽

Controlled Study ◽

Dosing Regimen ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

FRI0451 Secukinumab Provides Rapid and Sustained Reductions in Dactylitis and Enthesitis in Patients with Psoriatic Arthritis: Analysis of Data from The Phase 3 Randomised, Multicentre, Double-Blind, Placebo-Controlled Future 2 Study: Table 1.

10.1136/annrheumdis-2016-eular.4174 ◽

2016 ◽

Vol 75 (Suppl 2) ◽

pp. 599.2-600

Author(s):

B. Kirkham ◽

P. Mease ◽

I. McInnes ◽

V. Bhosekar ◽

S. Mpofu ◽

...

Keyword(s):

Psoriatic Arthritis ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial

The Lancet ◽

10.1016/s0140-6736(17)31429-0 ◽

2017 ◽

Vol 389 (10086) ◽

pp. 2317-2327 ◽

Cited By ~ 162

Author(s):

Peter Nash ◽

Bruce Kirkham ◽

Masato Okada ◽

Proton Rahman ◽

Benard Combe ◽

...

Keyword(s):

Psoriatic Arthritis ◽

Tumour Necrosis Factor ◽

Tumour Necrosis ◽

Inadequate Response ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Tumour Necrosis Factor Inhibitors ◽

Necrosis Factor

Inhibition of radiographic progression across levels of composite index-defined disease activity in patients with active psoriatic arthritis treated with intravenous golimumab: results from a phase-3, double-blind, placebo-controlled trial

Arthritis Research & Therapy ◽

10.1186/s13075-020-2126-1 ◽

2020 ◽

Vol 22 (1) ◽

Author(s):

Philip Mease ◽

M. Elaine Husni ◽

Shelly Kafka ◽

Soumya D. Chakravarty ◽

Diane D. Harrison ◽

...

Keyword(s):

Psoriatic Arthritis ◽

Disease Activity ◽

Radiographic Progression ◽

Controlled Trial ◽

Composite Index ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo

228. Secukinumab, A Human Anti-Interleukin-17A Monoclonal Antibody, Improves Active Psoriatic Arthritis and Inhibits Radiographic Progression: Efficacy and Safety Data from a Phase 3 Randomized, Multicentre, Double-Blind, Placebo-Controlled Study

Rheumatology ◽

10.1093/rheumatology/kev089.115 ◽

2015 ◽

Keyword(s):

Monoclonal Antibody ◽

Psoriatic Arthritis ◽

Radiographic Progression ◽

Safety Data ◽

Controlled Study ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Interleukin 17A

SAT0271 Continued Improvement of Signs and Symptoms in Ustekinumab-Treated Patients with Active Psoriatic Arthritis: Week 52 Results of a Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study

10.1136/annrheumdis-2013-eular.1996 ◽

2013 ◽

Vol 72 (Suppl 3) ◽

pp. A674.2-A675

Author(s):

A. Kavanaugh ◽

I. B. McInnes ◽

A. B. Gottlieb ◽

L. Puig ◽

P. Rahman ◽

...

Keyword(s):

Psoriatic Arthritis ◽

Signs And Symptoms ◽

Controlled Study ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo